2024-09-02 - Analysis Report
## ABBV Stock Analysis Report

This report analyzes the stock performance of AbbVie Inc. (ABBV), a pharmaceutical company developing, manufacturing, and commercializing a broad range of medicines.

**1. Performance Comparison:**

ABBV has outperformed the S&P 500 (VOO) by **16.72%** over the period analyzed. Its cumulative return of **106.38%** surpasses the S&P 500's **89.66%**. This outperformance places ABBV at the **65.53rd** percentile of its historical performance relative to the S&P 500.

**2. Recent Price Movement:**

ABBV's current price is **$196.31**. Its 5-day moving average is **$196.05**, 20-day moving average is **$193.17**, and 60-day moving average is **$179.48**. This indicates a recent upward trend with a slight pullback in the last 5 days.

**3. Technical Indicators:**

* **RSI (74.27):** The stock is currently in the overbought territory, indicating a potential short-term correction.
* **PPO (-0.36):** A negative PPO indicates a downward momentum, suggesting the stock could be experiencing a near-term weakness.
* **Delta_Previous_Relative_Divergence (-3.27):** The negative value indicates a short-term downtrend in the stock's relative strength compared to its previous performance.
* **Expected_Return (16.29%):** The 5-year expected return based on current investment indicates a potential for significant returns.

**4. Recent Earnings and Outlook:**

ABBV's recent earnings have consistently exceeded analysts' expectations. The most recent quarter (2024-07-25) saw an EPS of **$2.65**, surpassing the expected EPS of **$2.57**.  This strong earnings performance, along with the expected growth in its core businesses, suggests a positive outlook for the company.

**5. Overall Analysis:**

ABBV has shown strong performance compared to the market benchmark (S&P 500). The stock is currently in overbought territory, with indicators suggesting a potential near-term pullback. However, its consistent earnings outperformance and positive future outlook suggest a favorable long-term investment opportunity. 

**6. Investment Recommendation:**

Given its strong performance and promising future prospects, ABBV remains a good investment option for investors seeking exposure to the pharmaceutical sector. While a short-term correction is possible, the long-term potential remains positive. Investors may consider dollar-cost averaging to mitigate potential risks associated with short-term volatility. 

**Disclaimer:** This analysis is based on publicly available data and should not be considered financial advice. It is recommended to conduct thorough research and consult with a financial advisor before making any investment decisions. 
